Animal Cell Technology: From Target to Market : Proceedings of the 17th ESACT Meeting Tylösand, Sweden, June 10-14, 2001

E. Lindner-Olsson

ISBN 10: 1402002645 / ISBN 13: 9781402002649

Published by Springer, Springer, 2001

About this Item

Druck auf Anfrage Neuware - Printed after ordering - This book captures, in the form of concise papers of limited length, the essence of the latest development in those fields of animal cell technology. We hope that it will become a useful resource of the most up to date information in Animal Cell Technology, at least until the next meeting in May 2003 in Spain. Elisabeth Lindner-Olsson Nathalie Chatzissavidou Elke Lullau Acknowledgements This meeting would not have been possible without the help of a large number of people, some of whom you will find mentioned below. In addition to the Organizing Committee and the Scientific Committee, Mrs Eva Ljung kvist and Mrs Ewa Engstrom of SKD Konferensservice have been most important to us. They have had to bear with us, scientists with specific demands for everything. Mrs Ewa Engstrom has also, together with Dr Bjorn Lundgren, organized the trade fare and the fund raising. Mr Henrik Levin at SKD has coordinated the distribution of all confirmation letters for oral presentations and posters as well as the coordination of the manuscripts for the proceedings. We would also like to thank Micael Worbin at TylOsand for local coordination. We have just had a stimulating, pleasant and enriching ESACT 2001 meeting. Your participation was a success and we feel privileged and honored that you decided to come to TylOsand.

Seller Inventory # 9781402002649

Bibliographic Details

• Title: Animal Cell Technology: From Target to Market : Proceedings of the 17th ESACT Meeting Tylösand, Sweden, June 10-14, 2001
• Publisher: Springer, Springer
• Publication Date: 2001
• Language: English
• ISBN 10: 1402002645
• ISBN 13: 9781402002649
• Binding: Buch
• Condition: Neu
• Dimensions: 241W x 160H x 41D millimeters 241 millimeters width by 160 millimeters height by 41 millimeters depth
• Weight: 1168 grams

About this title

Synopsis

This book is the lasting product, a resource of up-to-date information in the scientific literature for the field of animal cell technology, as it was presented during a pleasant and stimulating meeting in Tylösand, Sweden, in June 2001. The title of the meeting, From Target to Market, indicates the usefulness of Animal Cell Technology during all steps in the pharmaceutical development process. Following the biotech products reaching the market, it shows an upward trend in the contribution of biotech products to total New Molecular Entity output in the nineties, which continued until 1996 when biotech represented 25% of the annual output. Since then the proportion has been decreasing. A perceived hurdle from a market perspective is that a protein per definition is biodegradable and thus requires intravenous, or for some drugs subcutaneous administration. New promising administration technologies such as pulmonary delivery were highlighted at this meeting. The emphasis on project selection prior to entry in the development phase has triggered a portfolio management using more extensive preclinical data before a development decision is taken. Animal cells have become a very important tool in the drug discovery process. The next generation of products will evolve from applications such as gene therapy, novel vaccines, cell therapy, and gene regulation. Animal cell technology has a major role to play in the post-sequence era.

Synopsis

This book is the lasting product, a resource of up-to-date information in the scientific literature for the field of animal cell technology, as it was presented during a pleasant and stimulating meeting in Tylosand, Sweden, in June 2001. The title of the meeting, From Target to Market, indicates the usefulness of Animal Cell Technology during all steps in the pharmaceutical development process. Following the biotech products reaching the market, it shows an upward trend in the contribution of biotech products to total New Molecular Entity output in the nineties, which continued until 1996 when biotech represented 25 per cent of the annual output. Since then the proportion has been decreasing.A perceived hurdle from a market perspective is that a protein per definition is biodegradable and thus requires intravenous, or for some drugs subcutaneous administration. New promising administration technologies such as pulmonary delivery were highlighted at this meeting. The emphasis on project selection prior to entry in the development phase has triggered a portfolio management using more extensive preclinical data before a development decision is taken.

Animal cells have become a very important tool in the drug discovery process. The next generation of products will evolve from applications such as gene therapy, novel vaccines, cell therapy, and gene regulation. Animal cell technology has a major role to play in the post-sequence era.